ReviewCureus2025
Adamantinoma-Like Ewing Sarcoma of the Parotid Gland: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adamantinoma-like Ewing sarcoma of the parotid gland: A case report.Journal of clinical imaging science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adamantinoma-like Ewing sarcoma (ALES) is a rare malignant neoplasm, identified as a type of Ewing sarcoma (ES), characterized by the EWSR1::FLI1 translocation and a complex immunoprofile. Its various clinical, histopathological, and immunohistochemical features, along with a multitude of diseases in the differential diagnosis, make it a complex entity that requires special attention. Treatment involves parotidectomy alone or in combination with adjuvant chemoradiotherapy. A systematic electronic search was conducted through February 2025 in the PubMed and Scopus databases utilizing relevant Medical Subject Headings, without any time constraints. A total of 35 publications were identified using the keywords "adamantinoma-like Ewing sarcoma" AND "parotid". Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a total of 15 articles were included in this systematic review, all of which were case reports. Based on the limited information available, it appears that this tumor frequently demonstrates regression after treatment. However, given the small number of recorded cases, a clear survival rate associated with specific therapies remains uncertain. This highlights the importance of ongoing assessments and follow-ups to establish definitive outcomes for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.